LIPOSOME SUPPRESSION OF PROLIFERATIVE VITREORETINOPATHY - RABBIT MODEL USING ANTIMETABOLITE ENCAPSULATED LIPOSOMES INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Assil, K. K., Hartzer, M., Weinreb, R. N., NEHORAYAN, M., Ward, T., Blumenkranz, M. 1991; 32 (11): 2891-2897

Abstract

The effects of the antimetabolites, cytarabine (Ara-C) and 5-fluorouridine 5'-monophosphate (FUMP), encapsulated in multivesicular liposomes on formation of vitreous fibroproliferative membranes in New Zealand white (NZW) rabbits were studied. In pharmacokinetic studies, the drug half-life in the vitreous cavity was 124 hr after intravitreal administration of 1.0 mg of FUMP in liposomes. By contrast, the drug half-life after a single injection in nonliposome-treated controls was only 4.5 hr. In a heterologous dermal fibroblast model of proliferative vitreoretinopathy (PVR), there was a 92% decrease in frequency of tractional retinal detachments in rabbits receiving a single intravitreal injection of liposome-encapsulated 0.1 mg of FUMP compared with controls receiving liposomes without drug. A dose of 1 mg of Ara-C in liposome-treated rabbits was associated with only a 46% reduction in tractional detachment compared with controls. Multivesicular liposome-encapsulated FUMP may be useful for inhibiting formation of fibroproliferative membranes in the vitreous after vitreoretinal surgery.

View details for Web of Science ID A1991GL40700006

View details for PubMedID 1917392